Filing Details
- Accession Number:
- 0001104659-24-008327
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-30 17:03:13
- Reporting Period:
- 2024-01-26
- Accepted Time:
- 2024-01-30 17:03:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1454789 | Astria Therapeutics Inc. | ATXS | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1859284 | Christopher Morabito | C/O Astria Therapeutics, Inc. 75 State Street, Suite 1400 Boston MA 02109 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-01-26 | 800 | $3.87 | 800 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-01-26 | 800 | $11.02 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-01-29 | 9,200 | $3.87 | 9,200 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-01-29 | 9,200 | $11.15 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-26 | 800 | $0.00 | 800 | $3.87 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-29 | 9,200 | $0.00 | 9,200 | $3.87 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
99,200 | 2032-07-31 | No | 4 | M | Direct | |
90,000 | 2032-07-31 | No | 4 | M | Direct |
Footnotes
- This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.02, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.